The OncomineTM Pan-Cancer Cell-free NGS assay is designed to detect 982 hotspots in comparison to the targeted approach for the reference ddPCR test which interrogates specific EGFR, KRAS and BRAF mutations. This evidence concerns the gene KRAS and cancer.